Automatic Web Traffic Generator

Arrowhead Pharmaceuticals Could Become The Next Gilead

Currently, there is no FDA approved cure for HBV infections, but Arrowhead Pharmaceuticals released data that suggests that they might have found one. The HBV market is a massive one, making the stock ... read more

Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September

Arrowhead Pharmaceuticals ... with a higher dose, it could be a problem. The study also tested 300 mg and 400 mg doses, which will be presented at the annual meeting of the American Association for th... read more

Arrowhead’s Future Could Now Ride on Progress of Amgen Partnership

Arrowhead Pharmaceuticals has nothing left in clinical trials. But a separate partnership with another biotech company, Amgen, could signal where Arrowhead goes next. The strategy shift became necessa... read more

Janssen and Arrowhead strike $3.7bn RNAi deal

Janssen has struck a deal with Arrowhead Pharmaceuticals ... that allows hepatitis B to become established in the body, gaining exclusive worldwide rights to develop and market ARO-HBV, a subcutaneous ... read more

Gilead adds another shot on the NASH goal with $785M Yuhan pact

It has, however, like many in the field, seen setbacks in trials, although clearly not enough to see them walk away from a market that could be worth tens of billions in the next ... and Gilead, along... read more

Our Gilead Sciences Prediction In 2019 (Buy or Sell?)

The company has since agreed to sell itself to Bristol Myers (NYSE: BMY) for $74 billion, the biggest pharmaceutical ... out the gate but sales could pick up. Gilead’s pipeline also has interesting ca... read more

‘Acting’ in name only: Mulvaney staffs up West Wing

In the coming days, Mulvaney is also slated to interview Joe Grogan, a top health care official at the budget agency, to potentially become the next head of the Domestic ... A former top lobbyist for ... read more

Gilead - Medivation Too Costly, How About Smaller Fish Like Arrowhead In HBV Or A NASH Target?

Gilead needs to do something, anything, including buying or partnering with smaller companies, until it can close a big deal to offset Harvoni declines. Arrowhead pharmaceuticals ... field that could ... read more

Factbox: Bristol-Myers' $74 Billion Celgene Buy Has Investors Looking for Next Deal

GILEAD ... Madrigal Pharmaceuticals and Intercept Pharmaceuticals are among the leaders developing treatments to tap a market that could eventually be worth $30 billion. As they race towards regulator... read more

These Drugmakers May Be Next to Make an M&A Splash in 2019

A number of business development hiccups have placed the company “deep in the penalty box,” Loncar said, noting a deal could be perceived as a negative next ... Alexion Pharmaceuticals Inc., though sm... read more

The $35 billion race to cure a silent killer that affects 30 million Americans

Right now four companies are leading efforts to commercialize a drug to reverse the effects of NASH: Intercept Pharmaceuticals, Gilead Sciences ... in hopes it could become the first drug to win appro... read more

Arrowhead Stock Is Not Done Rallying After Its 38% Jump

revenue could potentially grow 53% annually, compared to the biotech average of 18.5%. On the stock market, Arrowhead stock’s rally is even more impressive because the iShares Nasdaq Biotechnology ETF ... read more